Morphoceuticals
Morphoceuticals is a pre-revenue biotechnology company developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration, leveraging the bioelectrome — the body's electrical communication networks — through proprietary ion channel modulators and wearable bioreactor devices.
- Company typePrivate
- Founded2020
- HeadquartersMarblehead, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Morphoceuticals does
Morphoceuticals is a pre-revenue biotechnology company founded in 2020 that is developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration. The company is building what it describes as the first atlas of the bioelectrome—a comprehensive map of the body's non-neural electrical communication networks that govern multi-cellular coordination, tissue integrity, and regenerative signaling. Its platform combines multi-omics analysis, bioelectric profiling, and AI to identify and manipulate bioelectric patterns, delivered through proprietary combinations of ion channel and gap junction modulators and a wearable bioreactor ("biodome") device. The company's most notable proof-of-concept was achieved in January 2022, when its scientific co-founders Michael Levin and David Kaplan demonstrated functional limb regeneration in adult African clawed frogs—a species that does not naturally regenerate complex limbs—with results published in Science Advances.
The company targets conditions inadequately served by existing modalities, including traumatic injuries, degenerative diseases, and organ failure. The U.S. limb-loss population alone represents an addressable market of approximately 185,000 amputations per year and a projected 3.6 million people living with limb loss by 2050. Morphoceuticals is a privately held Delaware corporation headquartered in Medford, Massachusetts, with 1-10 employees and no commercialized products. Its anticipated revenue model is licensing and royalties from pharmaceutical partners, but the company is currently funded through venture capital, having raised over $15 million in cumulative seed financings led by Juvenescence and Prime Movers Lab. The leadership team includes CEO Jim Jenson (former CEO of Dicerna Pharmaceuticals, acquired by Novo Nordisk for $3.3 billion) and Chairman Roger Pomerantz (former President/CEO of Seres Therapeutics; led 14 FDA-approved therapies at J&J and Merck).
The go-to-market motion is enterprise-oriented: Morphoceuticals is positioned as a platform company targeting eventual licensing or acquisition by large pharmaceutical companies. Distribution channels do not yet exist for commercial products; future commercialization would rely on traditional pharmaceutical distribution to healthcare providers and institutions. Marketing activity is currently limited to earned media coverage, scientific publications and presentations (TED, Science Advances, Cell, Nature Communications), and a corporate website — appropriate for a pre-revenue research-stage company building scientific credibility among investors, partners, and the academic community.
Morphoceuticals firmographics
Firmographics- Name
- Morphoceuticals
- Legal name
- Morphoceuticals, Inc.
- Website
- https://morphoceuticals.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Morphoceuticals is a pre-revenue biotechnology company developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration, leveraging the bioelectrome — the body's electrical communication networks — through proprietary ion channel modulators and wearable bioreactor devices.
- Ownership category
- akta.pro rank
Morphoceuticals industry classification
Industry- Product category
- Regenerative Medicine Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Morphoceuticals is headquartered
LocationHeadquarters
- HQ city
- Marblehead
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Morphoceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Electroceutical Therapeutics: Pre-revenue biotech company developing AI-guided electroceuticals for tissue repair and organ regeneration. Revenue generation model not yet established as company is in R&D stage.
- Platform Technology Licensing: The company may pursue licensing agreements with large pharmaceutical companies for its bioelectrome platform technology and therapeutic candidates.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Morphoceuticals product offering
Product offeringCore offering
Morphoceuticals is a TechBio company building the first atlas of the bioelectrome—the set of electrical communication networks within the body that coordinate tissue repair and organ regeneration. Using multi-omics analysis, bioelectric profiling, and proprietary AI techniques, the company discovers and develops ion channel and gap junction modulators (electroceuticals) intended to induce limb regeneration, repair tissues, regenerate organs, and treat channelopathies. The platform is delivered alongside wearable bioreactor devices (biodomes) that establish localized controlled environments for electroceutical delivery.
Product overview
Morphoceuticals is a TechBio company offering a platform technology centered on the first-ever atlas of the bioelectrome. The core platform combines multi-omics analysis, bioelectric profiling, and AI to map and manipulate the body's electrical communication networks. The technology is delivered through AI-guided electroceuticals (ion channel and gap junction modulators) and wearable bioreactor devices (biodomes) that enable targeted bioelectric signaling for tissue repair and organ regeneration. The company is pursuing applications in limb regeneration, wound healing, organ repair, and treatment of degenerative diseases and traumatic injuries.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioelectrome Atlas Platform First-ever atlas of the bioelectrome—a comprehensive map of electrical communication networks within the body that bind multi-cellular collectives together, built using multi-omics, bioelectric profiling, and proprietary AI techniques. Used as a discovery engine for identifying regenerative therapeutic targets.
- AI-Guided Electroceuticals Proprietary combinations of ion channel and gap junction modulators guided by AI to induce tissue regeneration, improve amputation stump health, promote organ regeneration, and treat channelopathies. Aimed at patients with traumatic injuries, degenerative diseases, and organ failure.
- Wearable Bioreactor (Biodome) Wearable device (biodome) that establishes a temporary hydrated and controlled environment at a stump or wound site, enabling localized delivery of electroceuticals to trigger regenerative bioelectric signaling. Used in combination with Morphoceuticals' ion channel and gap junction modulators.
Quantifiable outcome
- Functional limb regeneration achieved in adult African clawed frogs (species that does not naturally regenerate complex limbs)
- +2 more outcomes
Companies that use Morphoceuticals
Customer profileSegments1 record
Ideal customer profiles2 records
Morphoceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Morphoceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- LyGenesisminorLyGenesis CEO Michael Hufford serves on Morphoceuticals' Board of Directors, creating a strategic connection between the two regenerative medicine companies.
- Tufts UniversitycoreMorphoceuticals was co-founded by Tufts University researchers Michael Levin and David Kaplan. The company leverages groundbreaking research from Tufts including limb regeneration demonstrated in African clawed frogs. The Allen Discovery Center at Tufts is led by Dr. Levin.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Morphoceuticals competitors and assessment
Company assessmentBroad incumbents
- electroCore: Public bioelectronic medicine company with FDA-cleared vagus nerve stimulation devices for multiple neurological conditions. Comparable through its electroceutical approach and neuromodulation platform, though applied to non-regenerative indications.
- Saluda Medical: Commercial-stage neuromodulation/electroceutical company with closed-loop spinal cord stimulation platform. Comparable through its use of electrical signaling to treat disease, though focused on pain management rather than regeneration.
- eGenesis: Clinical-stage gene editing company developing human-compatible organs for xenotransplantation. Comparable through its novel approach to addressing organ failure and regenerative medicine ambitions, though via a different mechanism (xenotransplantation vs. bioelectric signaling).
- Lineage Cell Therapeutics: Public clinical-stage cell therapy company developing allogeneic cell transplants for neurodegenerative, oncologic, and regenerative indications. Comparable through its regenerative medicine platform and pursuit of novel tissue-restoration therapies.
- Organogenesis: Public regenerative medicine company commercializing advanced wound care and surgical biologics products. Comparable through its regenerative medicine focus and commercial-stage presence, though in adjacent tissue repair applications rather than whole-organ regeneration.
- MiMedx: Public regenerative medicine company marketing placental tissue allografts for wound care and surgical recovery. Comparable through its regenerative medicine positioning and focus on tissue repair, though in established wound healing markets rather than bioelectric approaches.
Direct peers
- LyGenesis: Clinical-stage cell therapy company developing in vivo organ regeneration using lymph nodes as bioreactors. Most directly comparable to Morphoceuticals through its regenerative medicine ambition, board-level connection (LyGenesis CEO Hufford serves on Morphoceuticals' board), and shared focus on organ regrowth without traditional transplantation.
- Humacyte: Public regenerative medicine company bioengineering human tissues and vessels for implantation. Comparable through its tissue engineering platform targeting regenerative applications and pursuit of FDA approval pathways for novel regenerative products.
- SetPoint Medical: Clinical-stage bioelectronic medicine company developing vagus nerve stimulation for inflammatory and autoimmune diseases. Closely comparable to Morphoceuticals through its bioelectric therapeutic modality and proprietary neuro-immune mechanism, though targeting different indications.
Emerging players
- InVivo Therapeutics: Clinical-stage company developing neural regeneration therapies for spinal cord injury and other CNS conditions. Comparable through its regenerative medicine focus and use of novel biomaterial-based approaches for nerve repair.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Morphoceuticals social profiles
Digital presenceMorphoceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Morphoceuticals leadership team
Management profileNumber of profiles
Profiles13 records
Morphoceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Morphoceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Morphoceuticals
What does Morphoceuticals do?
Morphoceuticals is a TechBio company building the first atlas of the bioelectrome—the set of electrical communication networks within the body that coordinate tissue repair and organ regeneration. Using multi-omics analysis, bioelectric profiling, and proprietary AI techniques, the company discovers and develops ion channel and gap junction modulators (electroceuticals) intended to induce limb regeneration, repair tissues, regenerate organs, and treat channelopathies. The platform is delivered alongside wearable bioreactor devices (biodomes) that establish localized controlled environments for electroceutical delivery.
Is Morphoceuticals a public or private company?
Morphoceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Morphoceuticals founded?
Morphoceuticals was founded in 2020. It employs 1 to 10 people.
Where is Morphoceuticals based?
Morphoceuticals is headquartered in Marblehead, United States, in the North America region.
How does Morphoceuticals make money?
Two revenue lines are on record. Electroceutical Therapeutics are the primary driver. The others are platform Technology Licensing.
Who are Morphoceuticals's main competitors?
Broad incumbents on record are electroCore, Saluda Medical, eGenesis, Lineage Cell Therapeutics, Organogenesis and MiMedx. Direct peers are LyGenesis, Humacyte and SetPoint Medical. InVivo Therapeutics is listed as an emerging player.
Does Morphoceuticals have an API?
No public API is recorded for Morphoceuticals.
What industry is Morphoceuticals in?
Morphoceuticals's product category is Regenerative Medicine Therapeutics. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 8731.